TeselaGen Releases Alpha Version of Tesela Copilot: An AI Agent for Accelerating Life Science Innovation

May 5, 2025 9:00 AM

TeselaGen, a leading provider of AI-augmented design and automation software for biotechnology, announced the recent alpha release of its powerful agentic Copilot, seamlessly integrated with TeselaGen's Platform for Biological R&D. This breakthrough solution harnesses advanced artificial intelligence to streamline experiment planning, accelerate data analysis, and enhance bioproduct development for researchers in molecular biology, biochemistry,...

Read more

Northway Biotech Launches Full-Service Viral Clearance Studies, Delivering Results Faster Than Industry Standards

May 5, 2025 6:45 AM

Northway Biotech, a biopharmaceutical contract development and manufacturing organization (CDMO), today announced the expansion of its protein-based and gene therapy service offerings with the addition of Viral Clearance Studies (VCS) capabilities. This strategic growth follows the opening of Northway Biotech's new Gene Therapy Center with dedicated cGMP facilities for virus-related projects.With six newly established, identical BSL-2...

Read more

Vicore to Present at the Nordea Equities Healthcare Seminar

May 2, 2025 2:20 AM

Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced participation in the 2025 Nordea Equities Healthcare Seminar:Location: Stockholm, SwedenFormat: Presentation and 1x1 meetingsPresentation Date and Time: Thursday, May 8 at 11:25 AM CETPresenter: Hans Jeppsson, CFOThe company's management will also be available for meetings at the conference.For...

Read more

PharmaNest Launches FibroMAP, the First Single-Fiber Phenotypic Tool for the Study of Fibrosis Across Biological Models and Indications

May 1, 2025 12:00 PM

PharmaNest Inc. announced today the launch of FibroMAP, a breakthrough computational platform for automated histological phenotyping of fibrosis across biological models and indications, marking a major advance in digital pathology and image analysis for drug discovery and development.FibroMAP leverages high-resolution, single-fiber, and spatially resolved datasets generated by PharmaNest's FibroNest platform. These datasets, highly dimensional...

Read more

Petros Pharmaceuticals Developing First-in-Industry SaaS Platform Utilizing AI and Electronic Health Records Intended to Facilitate Rx-OTC Switches

May 1, 2025 9:20 AM

Petros Pharmaceuticals, Inc. (Nasdaq:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over the counter ("OTC") drug development programs, today announces a concerted effort toward evolving into a smart healthcare technology company through the development of a SaaS platform designed to complement its proprietary web application (also known as a Software as a Medical Device, or SaMD). The...

Read more

enVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24

May 1, 2025 8:05 AM

enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today reported financial results for the first quarter 2025.Robert Berman, enVVeno Medical's Chief Executive Officer, commented "In the first quarter, we continued to present our compelling 1-year data from the U.S. pivotal trial at leading global, scientific conferences to socialize and engage...

Read more

Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences

May 1, 2025 8:01 AM

Tharimmune, Inc., (Nasdaq:THAR) ("Tharimmune" or the "Company") a clinical-stage biopharmaceutical company focused on developing innovative therapeutics in inflammation & immunology announced abstracts featuring clinical data on its lead drug candidate, TH104, have been accepted for presentation at the Digestive Disease Week (DDW) Annual Meeting and at the European Association for the Study of the Liver (EASL) International Liver Congress. Both...

Read more

Aspira Reaches Another ARPA-H Milestone, Eligible to Receive Additional $1.5 Million in Second Quarter

May 1, 2025 7:00 AM

Aspira Women's Health Inc. ("Aspira") (OTC PINK:AWHL), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the successful submission of its third development milestone of its Advanced Research Projects Agency for Health (ARPA-H) award.The third milestone focused heavily on additional analytical development steps. The milestone specifically required the completion of...

Read more

A Co-Founder of Athos Therapeutics, Dr. Michael E. Jung, Wins the National Academy of Sciences Award for Chemistry in Service to Society

April 30, 2025 11:30 AM

Athos Therapeutics, Inc. ("Athos"), a clinical stage biotechnology company pioneering the development of precision small molecule therapeutics for patients with immune-mediated diseases, is honored to announce that Dr. Michael E. Jung, a co-founder of Athos, was awarded the National Academy of Sciences Award for Chemistry in Service to Society.This highly prestigious award recognizes "the profound benefits of chemistry to society and how...

Read more

Change in Number of Shares and Votes in Alligator Bioscience AB

April 30, 2025 9:15 AM

During April 2025, the number of shares and votes in Alligator Bioscience AB (STO:ATORX) ("Alligator Bioscience") has decreased as a result of the redemption of all 779,169 outstanding series C shares, as well as the reverse split of ordinary shares, which were resolved by the extraordinary general meeting on 27 March 2025.As of 30 April 2025, the total number of shares and votes in Alligator Bioscience amounts to 16,905,477, of which all...

Read more

Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors

April 30, 2025 8:01 AM

Tharimmune, Inc., (NASDAQ:THAR) ("Tharimmune" or the "Company") a clinical-stage biopharmaceutical company focused on developing innovative therapeutics in inflammation & immunology, today announced the appointment of Clay Kahler and Gary Stetz to its Board of Directors, increasing the Tharimmune Board to nine Directors. As reported in a Form 8-K filed on April 25, 2025, Directors Leonard Mazur and Lynne Bui, M.D. have notified the Board that...

Read more

Resolutions at BioInvent's Annual General Meeting 2025

April 29, 2025 11:15 AM

The Annual General Meeting ("AGM") of BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) resolved to re-elect the Board members Natalie Berner, Kristoffer Bissessar, Thomas Hecht, Leonard Kruimer, Laura Lassouw-Polman, Nanna Lüneborg, Vincent Ossipow and Bernd Seizinger and to implement a long-term incentive program.The AGM voted in favor of adopting the income statements and balance sheets for the Group and the parent company for...

Read more

Jord BioScience Field Trials Deliver Breakthrough Consistency in Biological Crop Protection, Boosting Soybean Yields Across Midwest

April 29, 2025 10:00 AM

Jord BioScience, a leading science and analytics company providing customizable microbial solutions for agriculture, unveiled two years of field trial data showing its proprietary microbial solutions consistently outperform industry-standard treatments, increasing soybean yield by up to 3.1 bushels per acre across 16 Midwest locations-even under dramatically different weather conditions.The company's approach, powered by its 6,500-isolate global...

Read more

Petros Proprietary Technology Platform Aligns with April 15, 2025 President Trump Executive Order Advancing Rx-to-OTC Reclassification Reforms

April 29, 2025 9:20 AM

Petros Pharmaceuticals, Inc. (Nasdaq:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over the counter ("OTC") drug development programs, today highlights President Trump's April 15, 2025 Executive Order, titled, "Lowering Drug Prices By Once Again Putting Americans First" (the "Executive Order"), as a demonstration that the Company's recent strategic shift is well timed to the current...

Read more

Scipher Medicine and InnoSIGN Announce Partnership to Advance Precision Medicine in Immunology

April 29, 2025 9:00 AM

InnoSIGN, a company focused on industrializing RNAseq data through its proprietary signaling pathway technology and Scipher Medicine, a leading network biology, AI-data driven therapeutics company, today announced a strategic partnership aimed at advancing the understanding and treatment of complex immune-mediated diseases.The collaboration will leverage Scipher Medicine's unique RNA sequencing data from patients with autoimmune, inflammatory...

Read more

BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Cutaneous T-cell Lymphoma

April 29, 2025 6:15 AM

BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to BI-1808, a first-in-class anti-TNFR2 antibody, for the treatment of adults with relapsed or refractory mycosis fungoides and Sézary...

Read more

BioInvent International AB: Interim Report January - March 2025

April 29, 2025 2:20 AM

BioInvent International (STO:BINV)"The first quarter of 2025 was a highly productive period across clinical development, regulatory milestones, and strategic partnerships - positioning us for strong momentum through the remainder of the year."- Martin Welschof CEO of BioInvent.EVENTS IN THE FIRST QUARTER(R) Positive initial efficacy data from Phase 2a trial of triple combination of the company's lead anti-FcyRIIB antibody BI-1206, rituximab and...

Read more

Exercise Price Determined for the Exercise of Warrants Series TO 12 in Alligator Bioscience AB

April 28, 2025 2:30 PM

Alligator Bioscience (STO:ATORX)Alligator Bioscience AB ("Alligator Bioscience" or the "Company") hereby announces that the exercise price for warrants series TO 12 (the "warrants") has been determined to SEK 3.68. The exercise period for the warrants commences on 5 May 2025 and runs up to and including 19 May 2025. The last day of trading in the warrants is 15 May 2025.Alligator Bioscience carried out a rights issue of units during December...

Read more

Data4Cure Presents Advances in AI-Driven Drug Target Discovery and Cancer Subtyping at AACR 2025

April 28, 2025 10:00 AM

Data4Cure, Inc., a leading biomedical data-to-knowledge company, today announced the presentation of two new research abstracts at the 2025 American Association for Cancer Research (AACR) Annual Meeting. The presentations highlight Data4Cure's advances in AI-based approaches for drug target discovery and large-scale cancer subtyping using foundation models applied to large collections of sequencing data.In the first study, titled "Knowledge...

Read more

Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback

April 28, 2025 8:01 AM

Tharimmune, Inc., (Nasdaq:THAR) ("Tharimmune" or the "Company") a clinical-stage biopharmaceutical company focused on developing innovative therapeutics in inflammation & immunology, recently announced positive feedback from the U.S. Food and Drug Administration (FDA) regarding TH104. The agency confirmed that no additional clinical trials appear to be necessary prior to a 505(b)(2) New Drug Application (NDA) submission. TH104 is a buccal film...

Read more